Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan.
Ann Nucl Med. 2013 Jan;27(1):46-57. doi: 10.1007/s12149-012-0660-x. Epub 2012 Oct 20.
The aim of this study was to survey the 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) cancer screening program conducted in Japan.
The "FDG-PET cancer screening program" included both FDG-PET and positron emission tomography with computed tomography (PET/CT) with or without other combined screening tests that were performed for cancer screening in asymptomatic subjects. A total of 155,456 subjects who underwent the FDG-PET cancer screening program during 2006-2009 were analyzed.
Of the 155,456 subjects, positive findings suggesting possible cancer were noted in 16,955 (10.9 %). The number of cases with detected cancer was 1,912 (1.23 % of the total screened cases, annual range 1.14-1.30 %). Of the 1,912 cases of detected cancer, positive findings on FDG-PET were present in 1,491 cases (0.96 % of the total number of screened cases). According to the results of further examinations, the true positive rate for subjects with suggested possible cancer (positive predictive value) was 32.3 % with FDG-PET. Cancers of the colon/rectum, thyroid, lung, and breast were most frequently found (396, 353, 319, and 163 cases, respectively) with high PET sensitivity (85.9, 90.7, 86.8, 84.0 %, respectively). Prostate cancer and gastric cancer (165 and 124 cases, respectively) had low PET sensitivity (37.0 and 37.9 %, respectively). The Union for International Cancer Control (UICC) clinical stage of cancer found with the FDG-PET cancer screening program was mainly Stage I.
The FDG-PET screening program in Japan has detected a variety of cancers at an early stage. However, several cancers were found in repeated FDG-PET cancer screening program, indicating the limitation of a one-time FDG-PET cancer screening program. The value of the FDG-PET cancer screening program is left to the judgment of individuals with regard to its potentials and limitations.
本研究旨在调查日本开展的 18F-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)癌症筛查计划。
“FDG-PET 癌症筛查计划”包括 FDG-PET 和正电子发射断层扫描与计算机断层扫描(PET/CT),并结合或不结合其他联合筛查测试,用于无症状受试者的癌症筛查。共分析了 2006-2009 年间接受 FDG-PET 癌症筛查计划的 155456 名受试者。
在 155456 名受试者中,有 16955 名(10.9%)发现阳性结果提示可能患有癌症。检测到癌症的病例数为 1912 例(筛查总数的 1.23%,年范围为 1.14%-1.30%)。在 1912 例检出的癌症中,1491 例(筛查总数的 0.96%)在 FDG-PET 上有阳性发现。根据进一步检查的结果,提示可能患有癌症的受试者的阳性预测值(阳性预测值)为 32.3%。结直肠癌、甲状腺癌、肺癌和乳腺癌最常见(分别为 396、353、319 和 163 例),PET 敏感性高(分别为 85.9%、90.7%、86.8%和 84.0%)。前列腺癌和胃癌(分别为 165 和 124 例)的 PET 敏感性较低(分别为 37.0%和 37.9%)。FDG-PET 癌症筛查计划发现的国际癌症控制联盟(UICC)癌症临床分期主要为 I 期。
日本的 FDG-PET 筛查计划已在早期发现了多种癌症。然而,在重复的 FDG-PET 癌症筛查计划中发现了一些癌症,这表明单次 FDG-PET 癌症筛查计划存在局限性。FDG-PET 癌症筛查计划的价值取决于个人对其潜力和局限性的判断。